Printer Friendly

New technology from Packard Instrument allows pharmaceutical companies to take the lead in the race for life-saving drugs.

MERIDEN, Conn.--(BUSINESS WIRE)--Nov. 26, 1996--

Glaxo-Wellcome, the latest major pharmaceutical company to

embrace Discovery, a flourescence microplate analyzer

for high throughput drug discovery screening

Packard Instrument Co., a $120 million supplier to the world's largest pharmaceutical and biotechnology companies, today announced a collaboration with Glaxo-Wellcome of Stevenage, Hertfordshire, U.K., for Discovery, a non-isotopic high throughput screening analysis system based on a Nobel Prize winning chemistry to make drug discovery faster, safer and more cost effective.

Glaxo-Wellcome is the fifth major pharmaceutical company to embrace the new technology. Earlier this year, Packard announced similar collaborations with Bristol-Myers Squibb, Zeneca Pharmaceuticals, Rhone-Poulenc Rorer and Boehringer Ingleheim Pharmaceuticals. The pharmaceutical giants will use Packard's unique technology to apply a new screening process called Homogenous Time Resolved Fluorescence (HTRF). HTRF can replace older, conventional radioisotopic processes, reducing exposure risks and waste-disposal costs. Currently, six other major pharmaceutical and biotech companies are evaluating Discovery.

"The catalyst for Discovery in the marketplace is its high throughput screening capacity," said Richard McKernan, president of Packard Instruments Co. "Given the advances in combinatorial chemistry and human genome research, pharmaceutical companies have widely accepted high throughput screening as the fastest method to identify potential drug candidates. With Discovery, researchers will be able to increase their daily screening capacity ten fold."

Another advantage of HTRF is that it allows researchers to "mix and measure" potential compounds with targets, eliminating the time-consuming washing and separating steps associated with traditional isotopic assay methods.

"Glaxo-Wellcome is committed to the target of launching three new medicines per year by the year 2000," said Dr. John Houston, research unit head for lead discovery of Glaxo-Wellcome Research and Development. "Discovery is one of several high technology tools our company will use to achieve this goal and maintain our leading position in the industry."

Packard is the first and only company to market the patented HTRF chemistry from CIS bio international of Gif-Sur-Yvette, France. Using Packard's high-capacity microplate analyzer Discovery, designed specifically for automated drug screening, HTRF can screen a remarkable 50,000 samples per day, compared to only 10,000 per day using conventional technology.

McKernan of Packard believes that innovative companies such a Glaxo-Wellcome will establish HTRF as a cornerstone for drug discovery into the next century. Going forward, Packard is looking to develop a family of products based on the HTRF assay methodology.

Packard Instrument Co., an innovator in instruments and reagents for life science research and drug discovery for more than 40 years, is a subsidiary of Canberra Industries, Meriden, Conn. Packard products and applications help worldwide organizations find new ways to conduct research and develop products in life science, diagnostics and environmental analysis. Packard employs more than 550 people worldwide with 50 employees at its corporate headquarters in Meriden and 275 at its manufacturing facility in Downers Grove, Ill.

For more information, contact Packard Instrument Co. at 1-800-323-1891 (U.S. only) or 203-238-2351, or visit our Web site at http://www.packardinst.com

CONTACT: Packard Instrument Co.

Betsy Walsh, 203/639-2330

or

Mintz & Hoke PR

Mary Ann Dostaler, 860/679-9701
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 26, 1996
Words:511
Previous Article:IBM board authorizes up to $3.5 billion for additional stock repurchases.
Next Article:AlliedSignal names new head for its Riedel-de Haen Unit.
Topics:


Related Articles
AIDS and Developing Countries: Democratizing Access to Essential Medicines.
Saving Lives.
Goddamn the Pusher Man.
BIACORE'S NEW ADVANCED SYSTEM SET TO DRAMATICALLY REDUCE DRUG DISCOVERY AND DEVELOPMENT BOTTLENECKS; BIACORE LAUNCHES NEW HIGH PERFORMANCE ANALYTICAL...
EDITORIAL : LEARNING FROM TURKEY.
Global public health: access to essential medicines.
The race to prescribe: drug for African Americans may debut amid debate.
Domestic treatment access in 2005: warning: do not read this without the aid of a good antidepressant!

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters